Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation

Journal of Human Hypertension

Volumn 30, Issue 6, 2016, Pages 368-373

  Patel, P ^a,b,c   Gupta, P K C ^a,b,c   White, C M J ^a,b   Stanley, A G ^a   Williams, B ^d,e   Tomaszewski, M ^a,b,c  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c GLENFIELD HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DENERVATION; MALE; MASS SPECTROMETRY; MEDICATION COMPLIANCE; PATIENT REFERRAL; RESISTANT HYPERTENSION; SCREENING TEST; SYSTOLIC BLOOD PRESSURE; TUNICA ALBUGINEA; URINALYSIS; BLOOD PRESSURE; CLINICAL DECISION MAKING; DRUG EFFECTS; DRUG MONITORING; DRUG RESISTANCE; INNERVATION; KIDNEY; KIDNEY ARTERY; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROCEDURES; RETROSPECTIVE STUDY; SYMPATHECTOMY; TANDEM MASS SPECTROMETRY; URINE; VASCULARIZATION;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL DECISION-MAKING; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; REFERRAL AND CONSULTATION; RENAL ARTERY; RETROSPECTIVE STUDIES; SYMPATHECTOMY; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 84943327721     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2015.103     Document Type: Article

References (44)

1. De la Sierra A, Segura J, Banegas JR, Gorostidi M, De la Cruz JJ, Armario P et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57: 898-902.
2. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635-1642.
3. Hayek SS, Abdou MH, Demoss BD, Legaspi JM, Veledar E, Deka A et al. Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients. Am J Hypertens 2013; 12: 1452-1458.
4. Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res 2015; 116: 1074-1095.
5. Calhoun DA, Booth JN 3rd, Oparil S, Irvin MR, Shimbo D, Lackland DT et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014; 63: 451-458.
6. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014; 64: 1012-1021.
7. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K et al. Catheterbased renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
8. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE et al. Renal sympathetic denervation in patients with treatmentresistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.
9. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917.
10. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.
11. Lobo MD, De Belder MA, Cleveland T, Collier D, Dasgupta I, Deanfield J et al. British Hypertension Society; British Cardiovascular Society; British Cardiovascular Intervention Society; Renal Association. Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension. Heart 2015; 101: 10-16.
12. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837-841.
13. Persu A, Jin Y, Baelen M, Vink E, Verloop WL, Schmidt B et al. Eligibility for renal denervation: experience at 11 European expert centers. Hypertension 2014; 63: 1319-1325.
14. Olsen LK, Kamper AL, Svendsen JH, Bang LE, Frimodt-Moller M, Kelbaek H et al. High incidence of secondary hypertension in patients referred for renal denervation-The Copenhagen experience. Blood Press 2014; 23: 233-239.
15. Savard S, Frank M, Bobrie G, Plouin PF, Sapoval M, Azizi M. Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. J Am Coll Cardiol 2012; 60: 2422-2424.
16. Verloop WL, Vink EE, Voskuil M, Vonken EJ, Rookmaaker MB, Bots ML et al. Eligibility for percutaneous renal denervation: The importance of a systematic screening. J Hypertens 2013; 31: 1662-1668.
17. Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol 2014; 63: 834-835.
18. De Oliveira-Filho AD, Costa FA, Neves SJ, De Lyra Junior DP, Morisky DE. Pseudoresistant hypertension due to poor medication adherence. Int J Cardiol 2014; 172: e309-e310.
19. Gosmanova EO, Kovesdy CP. Adherence to antihypertensive medications: is prescribing the right pill enough?. Nephrol Dial Transplant 2015; 30: 1649-1656.
20. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-Tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014; 100: 855-861.
21. NICE. CG127 Hypertension: Clinical management of primary hypertension in adults 2011. http://www.nice.org.uk/CG127. Accessed 19 December 2014.
22. McManus RJ, Caulfield M, Williams B. National Institute for Health and Clinical Excellence. NICE hypertension guideline 2011: evidence based evolution. BMJ 2012; 344: e181.
23. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
24. Azizi M, Sapoval MG, Gosse P, Monge M, Bobrie G, Delsart P et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015; 385: 1957-1965.
25. Rosa J, Widimsky P, Tousek P, Petrak O, Curila K, Waldauf P et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension 2015; 65: 407-413.
26. Rosa J, Zelinka T, Petrak O, Strauch B, Somloova Z, Indra T et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?. J Hum Hypertens 2014; 28: 684-688.
27. Pickering TG, Gerin W, Schwartz AR. What is the white-coat effect and how should it be measured?. Blood Press Monit 2002; 7: 293-300.
28. Tomaszewski M, Lacka B, Zukowska-Szczechowska E, Grzeszczak W, Gosek K. The evaluation of hypertensive patients' adherence to the pharmacological treatment of hypertension. Wiad Lek 1999; 52: 573-580.
29. Chung O, Vongpatanasin W, Bonaventura K, Lotan Y, Sohns C, Haverkamp W et al. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens 2014; 32: 2411-2421.
30. Ross S, Walker A, MacLeod MJ. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. J Hum Hypertens 2004; 18: 607-613.
31. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; 2: CD004804.
32. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for longterm conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS ONE 2013; 8: e80633.
33. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H et al. Resistant hypertension?. Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31: 766-774.
34. Fitzgerald RL, Rivera JD, Herold DA. Broad spectrum drug identification directly from urine, using liquid chromatography-Tandem mass spectrometry. Clin Chem 1999; 45: 1224-1234.
35. Mazzarino M, De la Torre X, Botre F. A screening method for the simultaneous detection of glucocorticoids, diuretics, stimulants, anti-oestrogens, betaadrenergic drugs and anabolic steroids in human urine by LC-ESI-MS/MS. Anal Bioanal Chem 2008; 392: 681-698.
36. Murray GJ, Danaceau JP. Simultaneous extraction and screening of diuretics, betablockers, selected stimulants and steroids in human urine by HPLC-MS/MS and UPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 3857-3864.
37. Moffat A, Osselton D, Widdop B, Watts J. Clarke's Analysis of Drugs and Poisons, 4th edn, Pharmaceutical Press: London, UK, 2011.
38. Hocht C, Bertera FM, Mayer MA, Taira CA. Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers. Expert Opin Drug Metab Toxicol 2010; 6: 199-211.
39. Zisaki A, Miskovic L, Hatzimanikatis V. Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches. Curr Pharm Des 2015; 21: 806-822.
40. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008; 10: 348-354.
41. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336: 1114-1117.
42. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012; 52: 275-301.
43. Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjonnaess E, Hjornholm U et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013; 62: 526-532.
44. Chatterjee JS. From compliance to concordance in diabetes. J Med Ethics 2006; 32: 507-510.